Immune privilege of corneal allografts

Jerry Y. Niederkorn, D. Frank P Larkin

Research output: Contribution to journalReview articlepeer-review

85 Scopus citations


Corneal transplantation has been performed successfully for over 100 years. Normally, HLA typing and systemic immunosuppressive drugs are not utilized, yet 90% of corneal allografts survive. In rodents, corneal allografts representing maximal histoincompatibility enjoy >50% survival even without immunosuppressive drugs. By contrast, other categories of transplants are invariably rejected in such donor/host combinations. The acceptance of corneal allografts compared to other categories of allografts is called immune privilege. The cornea expresses factors that contribute to immune privilege by preventing the induction and expression of immune responses to histocompatibility antigens on the corneal allograft. Among these are soluble and cell membrane molecules that block immune effector elements and also apoptosis of T lymphocytes. However, some conditions rob the corneal allograft of its immune privilege and promote rejection, which remains the leading cause of corneal allograft failure. Recent studies have examined new strategies for restoring immune privilege to such high-risk hosts.

Original languageEnglish (US)
Pages (from-to)162-171
Number of pages10
JournalOcular Immunology and Inflammation
Issue number3
StatePublished - Jun 2010


  • Corneal allografts
  • Immune privilege
  • Keratoplasty
  • Transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Immune privilege of corneal allografts'. Together they form a unique fingerprint.

Cite this